• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[胱氨酸病:诊断、胱氨酸消耗疗法及过渡]

[Cystinosis : Diagnosis, cystine-depleting therapy, and transition].

作者信息

Kaufeld Jessica, Weber Lutz T, Kurschat Christine, Canaan-Kuehl Sima, Brand Eva, Oh Jun, Pape Lars

机构信息

Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Hannover, Deutschland.

Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinik Köln, Köln, Deutschland.

出版信息

Internist (Berl). 2018 Aug;59(8):861-867. doi: 10.1007/s00108-018-0416-3.

DOI:10.1007/s00108-018-0416-3
PMID:29671012
Abstract

This article presents a case of cystinosis in a young man. Diagnosis of the disease and the problem of transition to adult care are described. Cystinosis is a rare lysosomal storage disease with first manifestation in early childhood presenting as renal Fanconi syndrome. Without treatment, the disease leads to severe health impairment. Due to the rarity of the disease, a correct diagnosis is often delayed. Without treatment, cystinosis often leads to end-stage renal failure, blindness, hypothyroidism, diabetes mellitus, and rickets. Cystine-depleting therapy with cysteamine significantly improves mortality and quality of life.

摘要

本文介绍了一名年轻男性的胱氨酸贮积症病例。描述了该疾病的诊断以及向成人护理过渡的问题。胱氨酸贮积症是一种罕见的溶酶体贮积病,最早在幼儿期表现为肾性范科尼综合征。未经治疗,该疾病会导致严重的健康损害。由于该疾病罕见,正确诊断往往会延迟。未经治疗,胱氨酸贮积症常导致终末期肾衰竭、失明、甲状腺功能减退、糖尿病和佝偻病。用半胱胺进行的耗胱氨酸疗法可显著提高生存率和生活质量。

相似文献

1
[Cystinosis : Diagnosis, cystine-depleting therapy, and transition].[胱氨酸病:诊断、胱氨酸消耗疗法及过渡]
Internist (Berl). 2018 Aug;59(8):861-867. doi: 10.1007/s00108-018-0416-3.
2
Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.胱氨酸病:与胱氨酸消耗疗法依从性相关的肾小球和肾小管功能
Pediatr Nephrol. 2015 Jun;30(6):945-51. doi: 10.1007/s00467-014-3018-x. Epub 2014 Dec 20.
3
Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.肾性胱氨酸病的争议和研究议程:“改善全球肾脏病预后组织”(KDIGO)争议会议的结论。
Kidney Int. 2016 Jun;89(6):1192-203. doi: 10.1016/j.kint.2016.01.033.
4
Effects of long-term cysteamine treatment in patients with cystinosis.胱氨酸病患者长期半胱胺治疗的效果。
Pediatr Nephrol. 2019 Apr;34(4):571-578. doi: 10.1007/s00467-017-3856-4. Epub 2017 Dec 19.
5
[Peculiarity of infantile cystinosis in Tunisian children].[突尼斯儿童婴儿型胱氨酸病的特点]
Pan Afr Med J. 2015 Dec 11;22:348. doi: 10.11604/pamj.2015.22.348.7727. eCollection 2015.
6
Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.肾病性胱氨酸病患者从速释型半胱胺转换为缓释型半胱胺:一项回顾性真实单中心研究。
Pediatr Nephrol. 2017 Jan;32(1):91-97. doi: 10.1007/s00467-016-3438-x. Epub 2016 Jun 27.
7
[Cystinosis in adults: A systemic disease].成人胱氨酸病:一种全身性疾病
Nephrol Ther. 2015 Jun;11(3):152-9. doi: 10.1016/j.nephro.2014.12.001. Epub 2015 Mar 11.
8
Pharmacological treatment of nephropathic cystinosis with cysteamine.用半胱胺对肾病性胱氨酸病进行药物治疗。
Expert Opin Pharmacother. 2004 Nov;5(11):2255-62. doi: 10.1517/14656566.5.11.2255.
9
Extrarenal complications of cystinosis.胱氨酸病的肾外并发症。
Pediatr Nephrol. 2024 Aug;39(8):2283-2292. doi: 10.1007/s00467-023-06225-0. Epub 2023 Dec 21.
10
Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.胱胺治疗在生命的头 2 个月开始对婴儿胱氨酸病的肾小球和肾小管肾脏功能的有益影响。
Mol Genet Metab. 2022 Aug;136(4):282-288. doi: 10.1016/j.ymgme.2022.06.009. Epub 2022 Jul 1.

本文引用的文献

1
Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.肾病性胱氨酸病患者从速释型半胱胺转换为缓释型半胱胺:一项回顾性真实单中心研究。
Pediatr Nephrol. 2017 Jan;32(1):91-97. doi: 10.1007/s00467-016-3438-x. Epub 2016 Jun 27.
2
Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.肾性胱氨酸病的争议和研究议程:“改善全球肾脏病预后组织”(KDIGO)争议会议的结论。
Kidney Int. 2016 Jun;89(6):1192-203. doi: 10.1016/j.kint.2016.01.033.
3
Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults.
西班牙胱氨酸病患者对半胱胺(Cystagon®)的依从性:儿童患者效果良好,青少年及成人患者面临挑战。
Nephrol Dial Transplant. 2015 Mar;30(3):475-80. doi: 10.1093/ndt/gfu329. Epub 2014 Oct 26.
4
Nephropathic cystinosis: an international consensus document.肾性胱氨酸病:一份国际共识文件。
Nephrol Dial Transplant. 2014 Sep;29 Suppl 4(Suppl 4):iv87-94. doi: 10.1093/ndt/gfu090.
5
Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.使用缓释型半胱胺酒石酸盐治疗2年的肾病性胱氨酸病患者生活质量得到改善,肾功能得以保留。
J Pediatr. 2014 Sep;165(3):528-33.e1. doi: 10.1016/j.jpeds.2014.05.013. Epub 2014 Jun 16.
6
Nephropathic cystinosis--a gap between developing and developed nations.肾病性胱氨酸病——发展中国家与发达国家之间的差距。
N Engl J Med. 2014 Apr 3;370(14):1366-7. doi: 10.1056/NEJMc1309480.
7
Executive function in nephropathic cystinosis.肾性胱氨酸病中的执行功能。
Cogn Behav Neurol. 2013 Mar;26(1):14-22. doi: 10.1097/WNN.0b013e31828b9f11.
8
Effect of age at treatment on cognitive performance in patients with cystinosis.胱氨酸病患者治疗时年龄对认知表现的影响。
J Pediatr. 2013 Aug;163(2):489-92. doi: 10.1016/j.jpeds.2013.01.027. Epub 2013 Feb 22.
9
A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.随机对照交叉试验延迟释放柠檬酸半胱氨酸盐在遗传性胱氨酸贮积症中的疗效:对白细胞半胱氨酸水平的影响和安全性比较。
Clin J Am Soc Nephrol. 2012 Jul;7(7):1112-20. doi: 10.2215/CJN.12321211. Epub 2012 May 3.
10
Cysteamine therapy: a treatment for cystinosis, not a cure.半胱胺疗法:治疗胱氨酸病的一种方法,而非治愈方法。
Kidney Int. 2012 Jan;81(2):127-9. doi: 10.1038/ki.2011.301.